The first review of Chinese Biopharmaceuticals

A few days ago, China biopharmaceutical announced that the new expectorant fludostam tablets (trade name: Zhongchang) of its subsidiary Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd was approved by the State Food and drug administration to pass the quality and efficacy consistency evaluation of generic drugs, and the same product is the first in China According to the data, Zhongchang was listed in 2009 for the first time in China Fludostam is a kind of slime dissolving agent It has comprehensive and fundamental expectorant effect It has high-efficiency antioxidant, synergistic hormone sensitization and anti-inflammatory, and is suitable for long-term use The drug has a good effect of mucolysis and excretion in many respiratory diseases It can delay the progress of COPD in the treatment of COPD Fordostan tablet is a clinical first-line therapeutic drug, which can be used in the whole department It was included in the national medical insurance catalog in 2017 Sales of China's public medical institutions' terminal fordostan (unit: 10000 yuan) according to the data of the intranet, in 2017, the sales of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal fordostan reached 224 million yuan, an increase of 21.25% year on year The dosage forms are tablet, capsule, powder and granule Among them, tablet has the largest market share, accounting for 60% In 2017, China's public medical institutions terminal fudostan tablet brand pattern the manufacturers of fudostan tablets are Disha Pharmaceutical Group, Jiangsu Zhengda Fenghai pharmaceutical, Sichuan Kelun pharmaceutical and Yichang dongyangjiang pharmaceutical Among them, Disha Pharmaceutical Group has the largest market share, accounting for 40.7%, followed by Jiangsu Zhengda Fenghai pharmaceutical, accounting for 33.63% In terms of consistency evaluation, in addition to Jiangsu zhengdafenghai Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., yichangdong Yangguang Changjiang Pharmaceutical Co., Ltd and Disha Pharmaceutical Group are also under review and approval (in the drug review center).